• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Legend Biotech Corp ADR (NQ: LEGN )

    45.02 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EDT, Oct 31, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Legend Biotech Corp ADR

    < Previous 1 2 3 4 Next >
    Legend Biotech to Host Investor Conference Call on Third Quarter 2024 Results
    From Legend Biotech USA Inc.
    Via GlobeNewswire
    Legend Biotech to Establish New, State-of-the-Art Cell Therapy Research and Development Facility in Philadelphia
    New 31,000 square-foot facility will enhance Legend’s leading cell therapy portfolio and expand Legend’s R&D capabilities as a global cell therapy leader 
    From Legend Biotech USA Inc.
    Via GlobeNewswire
    CARVYKTI® is the First and Only Cell Therapy to Significantly Extend Overall Survival Compared to Standard of Care in Patients with Multiple Myeloma as Early as Second Line
    From Legend Biotech USA Inc.
    Via GlobeNewswire
    Legend Biotech to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
    From Legend Biotech USA Inc.
    Via GlobeNewswire
    Legend Biotech Reports Second Quarter 2024 Results and Recent Highlights
    From Legend Biotech USA Inc.
    Via GlobeNewswire
    Legend Biotech Appoints Peter Salovey, Ph.D., to its Board of Directors
    From Legend Biotech USA Inc.
    Via GlobeNewswire
    Legend Biotech Announces Preliminary Results for the Six-Months Ended June 30, 2024
    From Legend Biotech USA Inc.
    Via GlobeNewswire
    CPI Data Sparks Rally in Biotech Stocks
    Following lower-than-expected inflation data on Thursday, The biotech sector broke out above resistance, closing the week up 6%, far outperforming the market. 
    Via MarketBeat
    Topics ETFs Economy
    Exposures Interest Rates
    Legend Biotech to Host Investor Conference Call on Second Quarter 2024 Results
    From Legend Biotech USA Inc.
    Via GlobeNewswire
    Legend Biotech Announces Positive Overall Survival Results of Landmark Phase 3 CARTITUDE-4 Trial in Multiple Myeloma
    CARVYKTI® demonstrated statistically significant and clinically meaningful improvement in overall survival in second interim analysis 
    From Legend Biotech USA Inc.
    Via GlobeNewswire
    Legend Biotech Shares Data on the Earliest Use to Date of CARVYKTI® in the Treatment of Multiple Myeloma and Important Subgroup Analyses at ASCO and EHA
    From Legend Biotech
    Via Business Wire
    Legend Biotech to Participate in the Jefferies Global Healthcare Conference
    From Legend Biotech Corporation
    Via Business Wire
    Legend Biotech to Highlight Leadership in CAR-T Cell Therapy for Patients with Multiple Myeloma at ASCO and EHA
    From Legend Biotech Corporation
    Via Business Wire
    Legend Biotech Reports First Quarter 2024 Results and Recent Highlights
    From Legend Biotech Corporation
    Via Business Wire
    CARVYKTI® (ciltacabtagene autoleucel) Approved by the European Commission for Second-line Treatment of Patients with Relapsed and Refractory Multiple Myeloma
    From Legend Biotech Corporation
    Via Business Wire
    Legend Biotech to Host Investor Conference Call on First Quarter 2024 Results
    From Legend Biotech Corporation
    Via Business Wire
    Legend Biotech’s CARVYKTI® (ciltacabtagene autoleucel) Becomes the First and Only BCMA-Targeted CAR-T Cell Therapy Approved by the FDA for Second-Line Treatment of Multiple Myeloma
    From Legend Biotech Corporation
    Via Business Wire
    Legend Biotech Announces Publication of Inaugural Environmental, Social and Governance (ESG) Report
    From Legend Biotech Corporation
    Via Business Wire
    CARVYKTI® (ciltacabtagene autoleucel) Receives Recommendation from the U.S. FDA Oncologic Drugs Advisory Committee for Earlier Treatment of Patients with Relapsed/Refractory Multiple Myeloma
    From Legend Biotech Corporation
    Via Business Wire
    Legend Biotech Reports Fourth Quarter and Full Year 2023 Results and Recent Highlights
    From Legend Biotech Corporation
    Via Business Wire
    Legend Biotech Announces Positive CHMP Opinion for CARVYKTI® (ciltacabtagene autoleucel) for the Treatment of Patients with Relapsed and Lenalidomide Refractory Multiple Myeloma in Earlier Lines of Therapy
    From Legend Biotech Corporation
    Via Business Wire
    Legend Biotech to Host Investor Conference Call on Fourth Quarter and Full Year 2023 Results
    From Legend Biotech Corporation
    Via Business Wire
    Legend Biotech Announces Closing of License Transaction for Certain CAR-T Therapies Targeting DLL3
    From Legend Biotech Corporation
    Via Business Wire
    Legend Biotech to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
    From Legend Biotech Corporation
    Via Business Wire
    Patient-Reported Outcomes from the CARTITUDE-4 Study Showed Clinically Meaningful Improvements in Health-Related Quality of Life and Reductions in Multiple Myeloma Symptoms Following Treatment with CARVYKTI® (ciltacabtagene autoleucel)
    From Legend Biotech Corporation
    Via Business Wire
    Legend Biotech Reports Third Quarter 2023 Results and Recent Highlights
    From Legend Biotech Corporation
    Via Business Wire
    Legend Biotech Announces Exclusive, Global License Agreement for Certain CAR-T Therapies Targeting DLL3
    From Legend Biotech Corporation
    Via Business Wire
    Legend Biotech to Host Investor Conference Call on Third-Quarter Results
    From Legend Biotech Corporation
    Via Business Wire
    Legend Biotech to Showcase Leadership in Multiple Myeloma Treatment at the ASH 2023 Annual Meeting
    From Legend Biotech Corporation
    Via Business Wire
    Legend Biotech Reports Second Quarter 2023 Results and Recent Highlights
    From Legend Biotech Corporation
    Via Business Wire
    < Previous 1 2 3 4 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.